ClinicalTrials.gg
RecruitingNCT07944066SAVE-ASUpdated Nov 18, 2026

SGLT2 Inhibitor in Patients With Asymptomatic Moderate or Severe Aortic Stenosis

A Phase 4 interventional study of Enavogliflozin and Placebo in Aortic Valve Stenosis, sponsored by Samsung Medical Center. Recruiting at 11 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Samsung Medical Center · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Jun 2026, registered Nov 2026).
  • Started Jun 2026; still recruiting 5 months later.
Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,182
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 25 studies in Aortic Valve Stenosis with a site in Korea, Republic of — 7 open to participants now, 11 under way, none of them phase 3. Aortic Valve Stenosis · Korea, Republic of.

Planned enrollment
Largest of 13
1,182 · median 145
Started
2026
with 1 other
Phase 4
9 of 25
3 open now
Primary completion
2031-06
later than 9 of 10 live
Registered
25th of 25
by date

Among the 25 studies in Aortic Valve Stenosis with a site in Korea, Republic of, this one has the largest planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2026, is one of 9 in phase 4, reaches primary completion later than 9 of the 10 other live ones, and was the 25th registered.

Aortic Valve Stenosis

1,027 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

7 of the 25 studies in Aortic Valve Stenosis with a site in Korea, Republic of are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 210 Aortic Valve Stenosis studies recruiting now, 164 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 25 take children under 18; 14 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Aortic Valve Stenosis with a site in Korea, Republic of, or all of them as a file.
02

Study summary

Aortic stenosis (AS) is the most common valvular heart disease, and no medical therapy has been shown to slow its progression; treatment is limited to surgical or transcatheter aortic valve replacement once symptoms or left ventricular dysfunction develop. Sodium-glucose cotransporter-2 (SGLT2) inhibitors reduce cardiovascular death and heart failure hospitalization in patients with and without diabetes, and preclinical studies show that they suppress the inflammatory (NLRP3 inflammasome), fibrotic (TGF-beta/Smad), and oxidative-stress pathways that drive valve calcification. A recent observational study reported slower AS progression in patients treated with SGLT2 inhibitors.

SAVE-AS is a multicenter, prospective, randomized, double-blind, placebo-controlled, investigator-initiated superiority trial testing whether the SGLT2 inhibitor enavogliflozin (0.3 mg once daily) reduces the composite of all-cause death, aortic valve replacement, and hospitalization for heart failure in adults with asymptomatic moderate or severe aortic stenosis and preserved left ventricular ejection fraction (50% or higher). A total of 1,182 participants at 11 centers in the Republic of Korea will be randomized 1:1 to enavogliflozin or matching placebo, stratified by participating center and AS severity (moderate vs severe). Study treatment is given for 24 months, with follow-up visits at 2, 6, 12, 18, and 24 months and an end-of-treatment assessment at 25 months. Secondary outcomes include the individual components of the primary composite, cardiac death, echocardiographic AS severity, left ventricular mass, global longitudinal strain and ejection fraction, NT-proBNP, annual eGFR slope, and SGLT2 inhibitor-related adverse events. All clinical events are adjudicated by an independent clinical event adjudication committee, and safety is overseen by an independent data and safety monitoring board.

Read the detailed description

Design: Prospective, multicenter (11 sites, Republic of Korea), randomized (1:1), double-blind, placebo-controlled, parallel-group, superiority, investigator-initiated trial. Randomization is performed centrally through an interactive web response system (IWRS) managed by an independent organization, stratified by participating center and baseline AS severity (moderate vs severe).

Population: Adults aged 19 years or older with asymptomatic (NYHA class I) moderate or severe aortic stenosis, defined as aortic valve area less than 1.5 cm2, peak aortic jet velocity 3 m/s or higher, or mean pressure gradient 25 mmHg or higher, with left ventricular ejection fraction 50% or higher. Patients meeting ACC/AHA or ESC/EACTS indications for aortic valve intervention, with very severe AS (peak velocity 5 m/s or higher or mean gradient 50 mmHg or higher), severe concomitant valve disease, eGFR below 30 mL/min/1.73 m2 or dialysis, type 1 diabetes, or SGLT2 inhibitor use within 3 months are excluded.

Intervention: Enavogliflozin 0.3 mg orally once daily or matching placebo for 24 months, on top of guideline-directed medical therapy per ACC/AHA/SCAI or ESC/EACTS recommendations. Concomitant medications may be adjusted at the investigator's discretion.

Schedule: Screening (day -90 to 0), baseline/randomization (day 0), visits at day 60 +/- 30, 180 +/- 30, 360 +/- 30, 540 +/- 30, and 720 +/- 30, and end-of-treatment assessment at day 750 +/- 90. Transthoracic echocardiography is performed at baseline, 12, and 24 months (and at 6 and 18 months in participants with severe AS at baseline). Laboratory tests (including eGFR), NT-proBNP and cardiac troponin T, ECG, and chest radiography are obtained at prespecified visits. Medication adherence is assessed at every visit. Clinical events are ascertained at each follow-up visit and at the end-of-treatment assessment at 25 months, and thereafter vital status and clinical events are ascertained by visit, telephone contact, or medical-record review until the end of study.

Sample size: Assuming an annual primary-event rate of 6% in the placebo group, a hazard ratio of 0.65, 3 years of accrual, 2 additional years of follow-up, 5% dropout, two-sided alpha of 0.05, and 80% power, 591 participants per group (1,182 total) are required (time-to-event analysis, log-rank test).

Analysis: Primary analysis by intention to treat; per-protocol analysis (adherence 70% or higher, no SGLT2 inhibitor use in the placebo group) as sensitivity analysis. Time-to-event outcomes are analyzed by Kaplan-Meier estimates, log-rank test, and Cox proportional-hazards models; continuous echocardiographic and laboratory outcomes by independent t-test. Participants lost to follow-up are censored. Prespecified subgroups: AS severity (moderate vs severe), age (below 70 vs 70 years or older), diabetes, hypertension, chronic kidney disease, and baseline global longitudinal strain. An interim analysis is planned when approximately 50% of the expected data have been collected, reviewed by the independent data and safety monitoring board.

Oversight: All primary and secondary clinical events are adjudicated by an independent Clinical Event Adjudication Committee. An independent Data and Safety Monitoring Board reviews all serious adverse events. Serious adverse events are reported to the principal investigator within 72 hours and to each site IRB per local requirements. The trial is conducted in accordance with the Declaration of Helsinki, ICH-GCP, and Korean GCP (KGCP).

03

Conditions studied

  • Aortic Valve Stenosis

Keywords

  • SGLT2 inhibitor
  • Enavogliflozin
  • Moderate aortic stenosis
  • Asymptomatic severe aortic stenosis
  • Medical therapy
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to understand the study protocol and provide written
  • Adults aged 19 years or older
  • Moderate or asymptomatic severe aortic stenosis, defined as all of the following:
  • Aortic valve area (AVA) less than 1.5 cm2, aortic valve peak velocity (Vmax) 3 m/s or higher, or aortic valve mean pressure gradient 25 mmHg or higher
  • 50% or higher
  • Asymptomatic, (NYHA) functional class I

Exclusion criteria

Exclusion Criteria:

  • below 50%
  • Indication for aortic valve intervention according to current ACC/AHA or ESC/EACTS guidelines
  • Symptomatic severe aortic stenosis
  • Severe stenosis or regurgitation of another valve, or concomitant severe aortic regurgitation
  • Very severe aortic stenosis (aortic valve Vmax 5 m/s or higher, or mean pressure gradient 50 mmHg or higher)
  • functional class II to IV
  • Use of an SGLT2 inhibitor within the previous 3 months
  • Known to SGLT2 inhibitors
  • Estimated below 30 mL/min/1.73 m2, or on dialysis
  • Type 1 diabetes mellitus
  • Pregnancy or breastfeeding
  • Liver disease with or ALT 2 or more times the , or history of hepatic encephalopathy, esophageal varices, or portosystemic shunt
  • below 2 years, or inability to comply with the study protocol
  • Diabetic ketoacidosis
  • Current use of medications that may affect efficacy assessment (DPP-4 inhibitors, vitamin K, calcium supplements)
  • Sexually active women of who do not agree to use adequate during the study
  • Participation in another clinical trial within the previous 1 month or 5 half-lives of the product
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,182 participants (estimated)

Study arms

  • Experimental
    Enavogliflozin

    Enavogliflozin 0.3 mg film-coated tablet orally once daily for 24 months, in addition to guideline-directed medical therapy.

    Drug: Enavogliflozin

  • Placebo comparator
    Placebo

    Matching placebo tablet (identical in appearance) orally once daily for 24 months, in addition to guideline-directed medical therapy.

    Drug: Placebo

Interventions

  • Sodium-glucose cotransporter-2 inhibitor, 0.3 mg film-coated tablet, taken orally once daily for 24 months.

    Also known as: Envlo

  • DrugPlacebo

    Matching placebo tablet identical in appearance to enavogliflozin, taken orally once daily for 24 months.

06

What researchers measure

Primary outcomes

  1. Composite of all-cause death, aortic valve replacement, or hospitalization for heart failure

    Time to first occurrence of any component of the composite: all-cause death; surgical or transcatheter aortic valve replacement; or hospitalization for heart failure, defined as presentation to an acute care facility requiring an overnight stay with symptoms and signs of heart failure and treatment with intravenous diuretics, vasodilators, or inotropes, mechanical fluid removal, intra-aortic balloon pump, or initiation/doubling of oral diuretics. All events are adjudicated by an independent clinical event adjudication committee.

    Time frame: From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months

Secondary outcomes

  1. All-cause death

    Time to death from any cause after randomization.

    Time frame: From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months

  2. Aortic valve replacement

    Time to first surgical or transcatheter aortic valve replacement after randomization.

    Time frame: From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months

  3. Hospitalization for heart failure

    Time to first adjudicated hospitalization for heart failure after randomization (presentation to an acute care facility requiring an overnight stay with symptoms and signs of heart failure and treatment with intravenous diuretics, vasodilators, or inotropes, mechanical fluid removal, intra-aortic balloon pump, or initiation/doubling of oral diuretics).

    Time frame: From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months

  4. Cardiac death

    Time to adjudicated cardiovascular death, including sudden cardiac death, death due to acute myocardial infarction, heart failure or cardiogenic shock, other cardiovascular causes, or death of unknown cause without an undisputed non-cardiac cause.

    Time frame: From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months

  5. Change from baseline in aortic valve peak velocity

    Change in peak aortic jet velocity (m/s) measured by transthoracic echocardiography.

    Time frame: Baseline, 12 months, and 24 months

  6. Change from baseline in mean transaortic pressure gradient

    Change in mean transaortic pressure gradient (mmHg) measured by transthoracic echocardiography.

    Time frame: Baseline, 12 months, and 24 months

  7. Change from baseline in aortic valve area

    Change in aortic valve area (cm2) calculated by the continuity equation on transthoracic echocardiography.

    Time frame: Baseline, 12 months, and 24 months

  8. Change from baseline in dimensionless index (velocity ratio)

    Change in the dimensionless index (velocity ratio), defined as the ratio of left ventricular outflow tract to transaortic velocity (or velocity-time integral), measured by transthoracic echocardiography; unitless.

    Time frame: Baseline, 12 months, and 24 months

  9. Change from baseline in left ventricular mass

    Change in echocardiographic left ventricular mass (g).

    Time frame: Baseline, 12 months, and 24 months

  10. Change from baseline in left ventricular global longitudinal strain

    Change in left ventricular global longitudinal strain (%) by speckle-tracking echocardiography.

    Time frame: Baseline, 12 months, and 24 months

  11. Change from baseline in left ventricular ejection fraction

    Change in left ventricular ejection fraction (%) by transthoracic echocardiography.

    Time frame: Baseline, 12 months, and 24 months

  12. Change from baseline in NT-proBNP

    Change in plasma N-terminal pro-B-type natriuretic peptide concentration (pg/mL).

    Time frame: Baseline, 12 months, and 24 months

  13. Annual eGFR slope

    Mean slope of change in estimated glomerular filtration rate (CKD-EPI equation), expressed as mL/min/1.73 m2 per year.

    Time frame: From baseline through 24 months

  14. Number of participants with at least one adverse event of special interest related to SGLT2 inhibition (safety)

    Number of participants experiencing one or more prespecified adverse events of special interest, reported as a single count per arm. Adverse events of special interest are: confirmed hypoglycemia (plasma glucose 70 mg/dL \[3.9 mmol/L\] or lower, or an event requiring assistance), urinary tract infection, genital infection, volume depletion, and acute kidney injury by KDIGO criteria.

    Time frame: From first dose of study drug through 7 days after the last dose (up to approximately 25 months)

07

Study locations

1 of 11 sites recruiting
  • Dong-A University Hospital
    Busan, South Korea
    Not yet recruiting
    • Kyung Hee Lim, MD, PhD · Principal investigator
  • Samsung Changwon Hospital
    Changwon, South Korea
    Not yet recruiting
    • Mirae Lee, MD, PhD · Principal investigator
  • Dankook University Hospital
    Cheonan, South Korea
    Not yet recruiting
    • Su Yeon Lee, MD, PhD · Principal investigator
  • Chung-Ang University Gwangmyeong Hospital
    Gwangmyeong, South Korea
    Not yet recruiting
    • Eun Jeong Cho, MD, PhD · Principal investigator
  • Seoul National University Bundang Hospital
    Seongnam, South Korea
    Not yet recruiting
    • Jiesuck Park, MD, PhD · Principal investigator
  • Samsung Medical Center
    Seoul, 06351, South Korea
    Recruiting
    • GaHee Lee · Contactgahee2.lee@sbri.co.kr · +82-2-2008-4135
    • Sung-Ji Park, MD, PhD · Principal investigator
  • Asan Medical Center, University of Ulsan College of Medicine
    Seoul, South Korea
    Not yet recruiting
    • Dae-Hee Kim, MD, PhD · Principal investigator
  • Kangbuk Samsung Hospital
    Seoul, South Korea
    Not yet recruiting
    • Jiwon Kim, MD, PhD · Principal investigator
  • Konkuk University Medical Center
    Seoul, South Korea
    Not yet recruiting
    • Sung Hea Kim, MD, PhD · Principal investigator
  • Korea University Anam Hospital
    Seoul, South Korea
    Not yet recruiting
    • So Ree Kim, MD, PhD · Principal investigator
  • Severance Hospital, Yonsei University College of Medicine
    Seoul, South Korea
    Not yet recruiting
    • Chi Young Shim, MD, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared outside the study group because the informed consent and institutional policy do not permit external release of participant-level data. Aggregate results will be published in a peer-reviewed journal and reported to ClinicalTrials.gov.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jun 2031, 60 months after the start.

Of 25 phase 4 interventional studies under Aortic Valve Stenosis, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 70. This study's planned 60 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2026
First posted
Nov 18, 2026
StartActual
Jun 10, 2026
Primary completionEst.
Jun 2031
CompletionEst.
Jun 2031
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07944066
Responsible party
Sung-Ji Park (Professor, Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center) — Principal investigator
First posted
Nov 18, 2026
Start date
Jun 10, 2026
Primary completion
Jun 2031 (estimated)
Completion
Jun 2031 (estimated)
Last update
Nov 18, 2026

Study contacts

GaHee Lee
Contact
gahee2.lee@sbri.co.kr
+82-2-2008-4135
Jinseon Heo
Contact
jinseon.heo@sbri.co.kr
Sung-Ji Park, MD, PhD
principal investigator · Samsung Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enavogliflozin

Start the discussion